← Back to patent-cliff list
PZH-2111
Tier C — Watch / tradePZH-2111
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：FGFR2, FGFR3
Indications (approved)：Cholangiocarcinoma, Solid tumour
Regional status
US
-
EU
-
China
Phase II
2022-01-07
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of PZH-2111?
Approved indications include: Cholangiocarcinoma, Solid tumour.
When does the PZH-2111 patent expire?
No public expiry year is available for PZH-2111 yet; this page updates once verified.
How do I get a quote for PZH-2111 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05